The text starts here.

News Release

FOR IMMEDIATE RELEASE
September 18, 2003

Eisai Launches SKAINAR(R) S TABLETS FOR RHINITIS
Containing Pseudoephedrine Hydrochloride for Nasal Congestion

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced today the launch of SKAINAR(R) S TABLETS FOR RHINITIS on September 19th, for alleviation of nasal congestion, runny nose, and sneezing caused by allergic or acute rhinitis.


SKAINAR(R) S TABLETS FOR RHINITIS is a small tablet which contains d-chlorpheniramine malate as an antihistamic agent, pseudoephedrine hydrochloride to relieve nasal congestion, belladonna alkaloid to relieve runny nose, and absolute caffeine to alleviate the heavy-head feeling associated with rhinitis. Pseudoephedrine hydrochloride is an active ingredient listed in the standard of manufacturing (import) approval for oral administration drug for rhinitis as a substitute for phenylpropanolamine hydrochroride (PPA), and SKAINAR(R) S TABLETS FOR RHINITIS is the first product which contains this ingredient in the SKAINAR(R) family of products.


Eisai had already launched medications for rhinitis which do not contain PPA, including SKAINAR(R) SOFT CAPSULE FOR RHINITIS, SKAINAR(R) COOL FOR RHINITIS, and SKAINAR(R) SPRAY FOR RHINITIS, since the launch of SKAINAR(R) N FOR RHINITIS in December 2001. Eisai seeks to satisfy various consumer needs through the launch of SKAINAR(R) S TABLETS FOR RHINITIS with the reinforced formulation to alleviate nasal congestion and runny nose, and aims to establish the SKAINAR(R) family of products as a major brand for rhinitis.


Sales of the SKAINAR(R) group are forecast for this fiscal year to be approximately 700 million yen.



For additional information about SKAINAR(R) products and Eisai's other consumer health care products, please contact Eisai's Consumer Hotline.

Toll Free Number (in Japan) : 0120 - 161 - 454
Monday-Friday 9 a.m. - 6 p.m.
Saturday/Sunday/Holiday 9 a.m. - 5 p.m.